Crossmark

Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems

Crossref DOI link: https://doi.org/10.1007/s10238-025-01558-6

Published Online: 2025-04-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aljabri, Ahmed https://orcid.org/0000-0002-7049-9826
Soliman, Ghareb M. https://orcid.org/0000-0002-9674-1254
Ramadan, Yasmin N. https://orcid.org/0009-0008-7374-9334
Medhat, Mohammed A. https://orcid.org/0000-0002-3866-2283
Hetta, Helal F. https://orcid.org/0000-0001-8541-7304
License Information

Text and Data Mining valid from 2025-04-05

Version of Record valid from 2025-04-05
More Information

Article History

Received: 2 October 2024

Accepted: 3 January 2025

First Online: 5 April 2025

Declarations

:

: The authors declare no competing interests.